OBJECTIVE: To reconstitute immune responses capable of eliminating infected cells and suppressing viral load during chronic retroviral infection. DESIGN: : A topical, DNA-based therapeutic immunization (DermaVir) was designed to express most of the regulatory and structural viral genes in dendritic cells. METHODS: DermaVir alone and in combination with antiretroviral drugs was tested in chronically SIV-infected macaques. RESULTS: DermaVir provided virological, immunological and clinical benefit for SIV-infected macaques during chronic infection and AIDS. In combination with antiretroviral drugs, DermaVir augmented SIV-specific T-cell responses and enhanced control of viral load rebound during treatment interruptions. CONCLUSIONS: The results indicate the feasibility of therapeutic immunization even in immune compromised hosts, and suggest that DermaVir can complement antiretroviral drugs to sustain suppression of HIV-1 replication.
OBJECTIVE: To reconstitute immune responses capable of eliminating infected cells and suppressing viral load during chronic retroviral infection. DESIGN: : A topical, DNA-based therapeutic immunization (DermaVir) was designed to express most of the regulatory and structural viral genes in dendritic cells. METHODS: DermaVir alone and in combination with antiretroviral drugs was tested in chronically SIV-infected macaques. RESULTS: DermaVir provided virological, immunological and clinical benefit for SIV-infected macaques during chronic infection and AIDS. In combination with antiretroviral drugs, DermaVir augmented SIV-specific T-cell responses and enhanced control of viral load rebound during treatment interruptions. CONCLUSIONS: The results indicate the feasibility of therapeutic immunization even in immune compromised hosts, and suggest that DermaVir can complement antiretroviral drugs to sustain suppression of HIV-1 replication.
Authors: Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas Journal: J Virol Date: 2006-07 Impact factor: 5.103
Authors: Antonio Valentin; Agneta von Gegerfelt; Margherita Rosati; Georgios Miteloudis; Candido Alicea; Cristina Bergamaschi; Rashmi Jalah; Vainav Patel; Amir S Khan; Ruxandra Draghia-Akli; George N Pavlakis; Barbara K Felber Journal: Vaccine Date: 2010-02-23 Impact factor: 3.641
Authors: Agneta S von Gegerfelt; Margherita Rosati; Candido Alicea; Antonio Valentin; Patricia Roth; Jenifer Bear; Genoveffa Franchini; Paul S Albert; Norbert Bischofberger; Jean D Boyer; David B Weiner; Phillip Markham; Zimra R Israel; John H Eldridge; George N Pavlakis; Barbara K Felber Journal: J Virol Date: 2006-11-29 Impact factor: 5.103
Authors: Benigno Rodriguez; David M Asmuth; Roy M Matining; John Spritzler; Jeffrey M Jacobson; Robbie B Mailliard; Xiao-Dong Li; Ana I Martinez; Allan R Tenorio; Franco Lori; Julianna Lisziewicz; Suria Yesmin; Charles R Rinaldo; Richard B Pollard Journal: J Acquir Immune Defic Syndr Date: 2013-12-01 Impact factor: 3.731
Authors: Orsolya Lőrincz; Enikő R Tőke; Eszter Somogyi; Ferenc Horkay; Preethi L Chandran; Jack F Douglas; János Szebeni; Julianna Lisziewicz Journal: Nanomedicine Date: 2011-08-10 Impact factor: 5.307
Authors: Deborah Heydenburg Fuller; Premeela Rajakumar; Jenny W Che; Amithi Narendran; Julia Nyaundi; Heather Michael; Eric J Yager; Cristy Stagnar; Brendon Wahlberg; Rachel Taber; Joel R Haynes; Fiona C Cook; Peter Ertl; John Tite; Angela M Amedee; Michael Murphey-Corb Journal: PLoS One Date: 2012-03-19 Impact factor: 3.240